Compare Citius Pharmaceuticals Inc (CTXR) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Stanley Black & Decker, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Stanley Black & Decker, Inc. trades at $88.68 (market cap $13.47B). The key difference: Stanley Black & Decker, Inc. is far larger — about 989× Citius Pharmaceuticals Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.77% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Stanley Black & Decker, Inc. for 62 Days on average.
| CTXR | SWK | |
|---|---|---|
Market Cap | $13.62M | $13.47B |
Volume | 132,438 | 2,859,744 |
Sector | Health | Industrials |
52-Week High | $1.82 | $104.00 |
52-Week Low | $0.48 | $62.12 |
Typical Hold Time | 17 Days | 62 Days |
Enterprise Value | $3.79M | $17.63B |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
Stanley Black & Decker (SWK) trades at $88.57, up 0.29% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $1.57 beating expectations of $1.21, and projected 2026 net income margin of 4.06%. Valuation appears reasonable with P/E of 21.8 and P/S of 0.89. Recent product launches include the dustbuster mini vacuum, while management focuses on margin improvement and DEWALT market share gains.
SWK presents a mixed outlook with analyst consensus at $93.00 (5% upside) but technical indicators signaling caution. The company's dividend king status provides income stability, though operational execution risks and competitive pressures remain concerns. Near-term catalyst includes Q3 2026 earnings release on November 4, 2026, which could validate margin improvement progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
